Back to mobile site

Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN)

December 8, 2025 9:26 AM EST Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $30.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst comments "Positve ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login